^
    3d
    AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, Children's Oncology Group | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate)
    23d
    ALL Backbone in AYAs (clinicaltrials.gov)
    P2, N=67, Not yet recruiting, Dana-Farber Cancer Institute
    New P2 trial
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • Purixan (mercaptopurine oral suspension)
    1m
    Efficacy and safety of DAPT regimen (dexamethasone, azacitidine, pegaspargase, tislelizumab) for NK/T cell lymphoma (ChiCTR2500109853)
    P2, N=50, Recruiting, Beijing Cancer Hospital; Beijing Cancer Hospital
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr) • azacitidine • Oncaspar liquid (pegaspargase)
    1m
    AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov)
    P3, N=5949, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6)
    |
    MLL rearrangement
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    2ms
    AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov)
    P3, N=847, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Sep 2026
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD22 (CD22 Molecule) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule) • MPO (Myeloperoxidase)
    |
    cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    2ms
    AALL2331: Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) (clinicaltrials.gov)
    P2/3, N=1708, Not yet recruiting, Children's Oncology Group | Initiation date: Sep 2025 --> Mar 2026
    Trial initiation date
    |
    cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Darzalex (daratumumab) • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • nelarabine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Purixan (mercaptopurine oral suspension) • Starasid (cytarabine ocfosfate)
    3ms
    CAALL-F01: A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents (clinicaltrials.gov)
    P3, N=2044, Active, not recruiting, Assistance Publique - Hôpitaux de Paris | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Mar 2027
    Enrollment closed • Trial completion date
    |
    Oncaspar liquid (pegaspargase)
    4ms
    DDGP-based chemoradiotherapy versus radiotherapy alone in newly diagnosed early-stage extranodal NK/T-cell lymphoma: A single-center retrospective analysis. (PubMed, Leuk Res)
    To determine the optimal treatment for early-stage extranodal NK/T-cell lymphoma (ENKTL), the efficacy differences between chemoradiotherapy (CRT) and radiotherapy (RT) alone, and between sequential DDGP (dexamethasone, cisplatin, gemcitabine, and pegaspargase) followed by RT (DDGP+RT) versus RT followed by DDGP (RT+DDGP) were investigated. CRT sequencing did not significantly affect survival outcomes. These findings demonstrate CRT's superiority over RT alone and suggest β2-MG may guide optimal treatment sequencing in early-stage ENKTL.
    Retrospective data • Journal
    |
    B2M (Beta-2-microglobulin)
    |
    LDH elevation
    |
    cisplatin • gemcitabine • Oncaspar liquid (pegaspargase)
    5ms
    Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) (clinicaltrials.gov)
    P2/3, N=1708, Not yet recruiting, Children's Oncology Group
    New P2/3 trial
    |
    cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Darzalex (daratumumab) • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • nelarabine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Purixan (mercaptopurine oral suspension) • Starasid (cytarabine ocfosfate)
    5ms
    Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, CStone Pharmaceuticals | Trial completion date: Nov 2028 --> Jun 2029 | Trial primary completion date: Nov 2027 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    gemcitabine • oxaliplatin • Cejemly (sugemalimab) • Oncaspar liquid (pegaspargase)
    5ms
    AALL1821: A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
    P2, N=461, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting | N=300 --> 461
    Enrollment open • Enrollment change
    |
    CD19 (CD19 Molecule)
    |
    Opdivo (nivolumab) • cytarabine • Blincyto (blinatumomab) • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Hemady (dexamethasone tablets) • ABP 206 (nivolumab biosimilar) • Asparec (PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    6ms
    A Study Comparing the Combination of Dasatinib or Imatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
    P3, N=222, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | N=680 --> 222
    Enrollment open • Enrollment change
    |
    ABL1 (ABL proto-oncogene 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CD19 (CD19 Molecule) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CSF1R (Colony stimulating factor 1 receptor)
    |
    TruSight RNA Pan-Cancer Panel
    |
    dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)